Literature DB >> 24091915

[RCT with 5-FU and mitomycin C with 28 fractions of 1.8 Gy external radiotherapy remains standard treatment of squamous-cell carcinoma of the anus].

G G Grabenbauer1.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24091915     DOI： 10.1007/s00066-013-0448-5

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  7 in total

1.  Tumor site predicts outcome after radiochemotherapy in squamous-cell carcinoma of the anal region: long-term results of 101 patients.

Authors:  Gerhard G Grabenbauer; Hermann Kessler; Klaus E Matzel; Rolf Sauer; Werner Hohenberger; Ignaz H F Schneider
Journal:  Dis Colon Rectum       Date:  2005-09       Impact factor: 4.585

2.  Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research.

Authors: 
Journal:  Lancet       Date:  1996-10-19       Impact factor: 79.321

3.  Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial.

Authors:  Didier Peiffert; Laetitia Tournier-Rangeard; Jean-Pierre Gérard; Claire Lemanski; Eric François; Marc Giovannini; Frédérique Cvitkovic; Xavier Mirabel; Olivier Bouché; Elisabeth Luporsi; Thierry Conroy; Christine Montoto-Grillot; Françoise Mornex; Antoine Lusinchi; Jean-Michel Hannoun-Lévi; Jean-François Seitz; Antoine Adenis; Christophe Hennequin; Bernard Denis; Michel Ducreux
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

4.  Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.

Authors:  Leonard L Gunderson; Kathryn A Winter; Jaffer A Ajani; John E Pedersen; Jennifer Moughan; Al B Benson; Charles R Thomas; Robert J Mayer; Michael G Haddock; Tyvin A Rich; Christopher G Willett
Journal:  J Clin Oncol       Date:  2012-11-13       Impact factor: 44.544

5.  Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study.

Authors:  M Flam; M John; T F Pajak; N Petrelli; R Myerson; S Doggett; J Quivey; M Rotman; H Kerman; L Coia; K Murray
Journal:  J Clin Oncol       Date:  1996-09       Impact factor: 44.544

6.  Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.

Authors:  Jaffer A Ajani; Kathryn A Winter; Leonard L Gunderson; John Pedersen; Al B Benson; Charles R Thomas; Robert J Mayer; Michael G Haddock; Tyvin A Rich; Christopher Willett
Journal:  JAMA       Date:  2008-04-23       Impact factor: 56.272

7.  Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.

Authors:  Roger D James; Robert Glynne-Jones; Helen M Meadows; David Cunningham; Arthur Sun Myint; Mark P Saunders; Timothy Maughan; Alec McDonald; Sharadah Essapen; Martin Leslie; Stephen Falk; Charles Wilson; Simon Gollins; Rubina Begum; Jonathan Ledermann; Latha Kadalayil; David Sebag-Montefiore
Journal:  Lancet Oncol       Date:  2013-04-09       Impact factor: 41.316
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.